IPO Watchlist: The Biopharma Unicorns That Could Go Public in 2024

2024 is shaping up to be a busy year for biopharma IPOs: Seven companies in the sector have already IPO’d since the start of the year, for a collective exit value of $3.1 billion. The largest of the lot, California-based CG Oncology, raised nearly $400 million in its Nasdaq IPO in January to fund the development of bladder cancer treatments. The upswell in IPOs has the potential to drive more drug companies to explore a public listing, according to PitchBook’s Q4 2023 Biopharma Report. Here are 10 US VC-backed biopharma unicorns with a high likelihood of going public. The list was created using PitchBook’s VC Exit Predictor, which calculates exit probability using a machine learning model that is fed historical and real-time data on private company exits.

Read the full article: IPO Watchlist: The Biopharma Unicorns That Could Go Public in 2024 //

Source: https://pitchbook.com/news/articles/ipo-watchlist-biopharma-unicorns-2024

Leave a Comment

Your email address will not be published.

Scroll to Top